Clinical trials: Prostate Cancer Recurrence After Radical Prostatectomy
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT06205316
- Testing
- Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Biochemical Recurrence
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with…
- Trial name
- NCT05753566
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer (Post Prostatectomy)
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
Prostate cancer patients with high-risk features who undergo radical prostatectomy (RP) are at a significant risk of biochemical recurrence (BCR) and disease progression.
- Trial name
- ARMOR (NCT07711314)
- Testing
- Rezvilutamide Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recurrent Prostate Carcinoma
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
This phase II trial compares how well gallium 68-labeled PSMA-11 positron emission tomography/computed tomography (PET/CT) works compared to fluciclovine F18 PET/CT in imaging participants with prostate cancer after surgery that…
- Trial name
- PSMA vs AXUMIN (NCT03515577)
- Testing
- Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
The purpose of this study is to describe the rate of 3-year progression free survival in men with recurrent PSA-only disease after prostatectomy, who receive combined apalutamide (ARN-509) and standard ADT with salvage radiation…
- Trial name
- NCT03311555
- Testing
- Apalutamide, Androgen deprivation, Salvage radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Andrew J. Armstrong, MD
Prostate
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a…
- Trial name
- NCT03047135
- Testing
- Olaparib
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms
Exisulind Versus Placebo After Surgical Removal of the Prostate
This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for…
- Trial name
- NCT00166426
- Testing
- Exisulind
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Biochemical Recurrence
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Recurrence, High Risk
- Trial name
- ARES (NCT05778097)
- Testing
- Apalutamide 60mg Tab, Androgen deprivation therapy(ADT)
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.
This is a a randomized phase II/III trial comparing salvage SBRT with standard of care (SOC) regimens for patients with a persistent detectable PSA or biochemical progression during follow-up after radical prostatectomy.
- Trial name
- STEREOBED (NCT06523634)
- Testing
- Stereotactic body radiotherapy (SBRT), SOC RT
- Where
- 13 sites in Belgium
- Volunteers
- 284 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00073970
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostatic Neoplasm
Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
After radical prostatectomy, 30-60% of patients will develop recurrent disease. Salvage radiotherapy, usually at 2 Gy per fraction, is the main treatment option for these patients.
- Trial name
- esSBRT (NCT05667636)
- Testing
- salvage SBRT
- Where
- Italy
- Volunteers
- 103 people
- Sponsor
- Regina Elena Cancer Institute
Recurrent Prostate Carcinoma
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after…
- Trial name
- PSMA SRT (NCT03582774)
- Testing
- Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 193 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy after surgery may kill more tumor cells.
- Trial name
- NCT00003858
- Testing
- mitoxantrone hydrochloride
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
LIpitor and biGuanide to Androgen Delay Trial
This study is a randomized trial examining the administration of a combination of biguanide metformin and atorvastatin ("Lipitor") to men who are experiencing rising prostate-specific antigen (PSA) levels, despite having…
- Trial name
- LIGAND (NCT02497638)
- Testing
- Metformin, Atorvastatin
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Biochemical Recurrence
Predictors of BCR After RARP for Localized Prostate Cancer: A Retrospective Analysis
This retrospective study aims to identify predictive factors for biochemical recurrence (BCR) in patients with localized prostate cancer who underwent robot-assisted radical prostatectomy (RARP).
- Trial name
- NCT07682584
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer, Sexual Dysfunction and Infertility
Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.
- Trial name
- NCT00003323
- Testing
- finasteride, flutamide, quality-of-life assessment
- Where
- 43 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer (Adenocarcinoma)
Predictive Factors for 10-year Biochemical Recurrence and Urinary Continence Following Robot-assisted Radical Prostatectomy for Prostate Cancer
The aim of the present project is to evaluate long-term oncological and functional treatment outcomes, as well as patient satisfaction, ten years after radical prostatectomy in patients initially enrolled in CPRRP study.
- Trial name
- NCT07439913
- Testing
- Radical prostatectomy
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Prostate Cancer
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional…
- Trial name
- NCT05169112
- Testing
- Lupron Depot
- Where
- 3 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer, Prostatectomy
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
The goal of this observational study is to learn about the long-term effects of HDR Brachytherapy in men with isolated local relapses after radical prostatectomy.
- Conditions
- Prostate Cancer, Prostatectomy, Local Recurrence of Malignant Tumor of Prostate, Radiotherapy; Complications
- Trial name
- NCT06982469
- Testing
- Brachytherapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra